EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Calithera Biosciences's enterprise value is $-1.35 Mil.
Calithera Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-41.82 Mil. Therefore, Calithera Biosciences's EV-to-EBITDA for today is 0.03.
The historical rank and industry rank for Calithera Biosciences's EV-to-EBITDA or its related term are showing as below:
CALA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.03
Current: 0.03
During the past 11 years, the highest EV-to-EBITDA of Calithera Biosciences was 0.03. The lowest was 0.00. And the median was 0.00.
CALA's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.22
vs CALA: 0.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Calithera Biosciences EV-to-EBITDA Historical Data
The historical data trend for Calithera Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Calithera Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, Calithera Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calithera Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calithera Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Calithera Biosciences's EV-to-EBITDA falls into.
Calithera Biosciences's current Enterprise Value is $-1.35 Mil.
Calithera Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Calithera Biosciences's PE Ratio for today is calculated as:
Calithera Biosciences's share price for today is $0.02.
Calithera Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Calithera Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Calithera Biosciences (Calithera Biosciences) Business Description
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CALA has been successfully added to your 